• 1

    Unpacking “MFN”: Japan Listed as Reference Country in US Pricing Models

  • 2

    PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy

  • 3

    Japan OKs Listing of Exdensur, Aquipta, Tukysa, and More; New Price Rules Applied to Two

  • 4

    AstraZeneca Lifts Japan Approval Target to 50-Plus by 2030 as Pipeline Advances

  • 5

    Sanofi Japan Chief Iwaya to Step Down at June End, Leave EFPIA Role